Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Immunosuppression can lead to hepatitis B virus (HBV) reactivation in hepatitis B core antigen antibodies (anti-HBc) positive patients, especially those undergoing chemotherapy, although there is limited data on solid organ recipients, especially lung transplantation. Our aim was to analyze the risk of HBV reactivation and the potential impact of anti-HBc-positive status (both donors and recipients) on prognosis in a lung, kidney, and liver transplantation cohort. Retrospective analysis including data from all transplants in adults (2011–2012) in a tertiary hospital, with prospective HBV serology study to assess the risk of reactivation and its possible impact on survival. In total, 392 transplant recipients were included (196 kidney, 113 lung, 83 liver). Pre-transplantation anti-HBc screening was more frequent in liver recipients (P < .001) and donors (P < .001) than in kidney or lung. Fifty-five (14%) recipients were anti-HBc-positive and were not undergoing antiviral prophylaxis. Three (5.4%) cases of HBV reactivation occurred: 2 in pre-transplant anti-HBc-positive recipients and 1 with prior unknown anti-HBc status. All were HBeAg+ with HBV deoxyribonucleic acid (DNA) >10E8 IU/mL and only mild fibrosis. Baseline recipient anti-HBc positive status was the only factor associated with HBV reactivation. No reactivation cases occurred in lung or kidney recipients of anti-HBc positive grafts. Survival was lower in lung transplants, especially in human immunodeficiency virus-infected patients and those with prior immunosuppression. Anti-HBc positive status is a risk factor for HBV reactivation in solid organ recipients. Anti-HBc testing is highly recommended in solid-organ transplant recipients in order to identify those anti-HBc positive and therefore candidates for periodical hepatitis B surface antigen (HBsAg) and HBV DNA screening after transplant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antivirals for HBV infection are available and safe to use post-transplant for prophylaxis and treatment. Consequently, HBV in patients without liver disease is not a barrier to lung transplant.(78)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there was no significant difference in the survival rate among hepatitis C virus seropositive patients who underwent lung transplantation, and there was no increase in mortality in patients without evidence of cirrhosis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [32]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“if there is no evidence of liver cirrhosis, hepatitis C virus infection can also be treated after surgery [31,32].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Self-citationTerrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306 · cited 4×
“Risk of reactivation varies according to HBV status and the type and duration of immunosuppressive therapy.([5,6]) In the transplantation setting, it is well recognized that the risk of HBV reactivation is very low in recipients receiving an antiHBc-positive solid organ, with the exception of liver grafts.”
BackgroundMethodInfluentialReddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.039 · Cited by 861
Loomba, R., & Liang, T. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.009 · Cited by 594
Perrillo, R. P., Gish, R., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.038 · Cited by 504
Liver grafts from anti-hepatitis B core positive donors: A systematic review
Cholongitas, E., Papatheodoridis, G. V., & Burroughs, A. K. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.009 · Cited by 294 · cited 1×
“Liver transplantation from anti-HBc-positive donors is linked with a high risk of de novo HBV infection and therefore, lifelong prophylaxis with nucleos(t)ides analogs (NUC) is recommended.([3,12]) Although anti-HBc positivity has been associated with a high risk of HBV reactivation, especially in patients with hemato…”
BackgroundHuang, H., Li, X., Zhu, J., Ye, S., Zhang, H., Wang, W., Wu, X., Peng, J., Xu, B., Lin, Y., et al. (2014) · JAMA · doi:10.1001/jama.2014.15704 · Cited by 232
Madayag, R. M., Johnson, L. B., Bartlett, S. T., Schweitzer, E. J., Constantine, N. T., McCarter, R., Kuo, P. C., Keay, S. K., & Oldach, D. (1997) · Transplantation · doi:10.1097/00007890-199712270-00027 · Cited by 88
HBV reactivation after kidney transplantation
Berger, A., Preiser, W., Kachel, H.-G., Stürmer, M., & Doerr, H. W. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.10.006 · Cited by 68 · cited 1×
“Research performed in Europe with smaller cohorts has reported similar reactivation rates.([17,21]) In lung transplant, previous studies have proved the safety of anti-HBc-positive grafts but, to our knowledge, there were no specific data on the potential role”
BackgroundKanaan, N., Kabamba, B., Maréchal, C., Pirson, Y., Beguin, C., Goffin, E. J., & Hassoun, Z. (2012) · Journal of Clinical Virology · doi:10.1016/j.jcv.2012.07.015 · Cited by 66 · cited 2×
“Research performed in Europe with smaller cohorts has reported similar reactivation rates.([17,21]) In lung transplant, previous studies have proved the safety of anti-HBc-positive grafts but, to our knowledge, there were no specific data on the potential role”
Background
Research works printed but not linked: 1
- Gonzalez, 2016, Hepatitis b reactivation among non-liver solid organ transplant recipients, Am J Transplant, 13
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Yin, S., Zhang, F., Wu, J., Lin, T., & Wang, X. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004196 · Cited by 23
Indications for Lung Transplantation and Patient Selection
Son, J., & Shin, C. (2022) · Journal of Chest Surgery · doi:10.5090/jcs.22.057 · Cited by 10
Hepatitis B virus reactivation in hepatitis B core antibody positive lung transplant recipients
Fernández‐García, O. A., Zelyas, N. J., Meier‐Stephenson, V., Halloran, K. M., & Doucette, K. E. (2023) · JHLT Open · doi:10.1016/j.jhlto.2023.100018 · Cited by 8
Moving towards core antigen for the management of patients with overt and occult HBV infection
Armandi, A., ROSSO, C., Ribaldone, D. G., & Caviglia, G. P. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04163-4 · Cited by 5
Metadata
- Authors
- Álvarez-López, P., Riveiro-Barciela, M., Oleas-Vega, D., Flores-Cortes, C., Román, A., Perelló, M., Berastegui, C., Castells, L., Esteban, R., & Buti, M.
- Affiliations
- Liver Unit, Internal Medicine Department
- Nephrology Department
- Vall d'Hebron Hospital Universitari (ES)
- Instituto de Salud Carlos III (ES)
- Venue
- Medicine
- Published
- 2020-02
- Volume
- 99
- Issue
- 9
- Pages
- e19407
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC7478413
- OpenAlex
- W3010313192
- Cited by
- 15
- References
- 23
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 2
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- HBV reactivation, anti-HBc, solid organ transplantation, lung transplantation, kidney transplantation, liver transplantation, immunosuppression, transplant recipient survival, HIV infection, HBV DNA, HBeAg
- MeSH terms
- Adult, Aged, Female, Hepatitis B, Hepatitis B Core Antigens, Humans, Male, Middle Aged, Prospective Studies, Retrospective Studies, Spain, Virus Activation, Survival Analysis, Organ Transplantation, Risk Assessment, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients. https://app.cochat.ai/papers/10.1097/md.0000000000019407
- The paper
- Álvarez-López, P., Riveiro-Barciela, M., Oleas-Vega, D., Flores-Cortes, C., Román, A., Perelló, M., Berastegui, C., Castells, L., Esteban, R., & Buti, M. (2020). Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients. Medicine. https://doi.org/10.1097/md.0000000000019407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.